Carbohydrates Or Derivatives Patents (Class 536/1.11)
  • Patent number: 10981942
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: April 20, 2021
    Assignee: THERACOS SUB, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
  • Patent number: 10913762
    Abstract: The present invention relates to process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl] methyl]phenyl]-, (1S) formula-1 and its crystalline forms thereof.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 9, 2021
    Assignee: MSN LABORATORIES PRIVATE LIMITED
    Inventors: Thirumalai Rajan Srinivasan, Eswaraiah Sajja, Venkata Panakala Rao Gogulapati, Rajeshwar Reddy Sagyam, Rajesham Boge, Mohammad Rafee Shaik
  • Patent number: 10793588
    Abstract: The present invention relates to a crystalline form of a co-crystal of an inhibitor against sodium-glucose cotransporter 2 with L-proline, a method for preparing the same, a pharmaceutical composition comprising the same, and use thereof. Specifically, the present invention relates to a crystalline form of a co-crystal of an inhibitor against sodium-glucose cotransporter 2 represented by formula (1), i.e., (2S,3R,4R,5S,6R)-2-(3-(4-(((1R,3s,5S)-bicyclo[3.1.0]hexan-3-yl)oxy)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, with L-proline, a method for preparing the same, a pharmaceutical composition comprising the same, and use thereof.
    Type: Grant
    Filed: May 27, 2017
    Date of Patent: October 6, 2020
    Assignees: JI LIN HUI SHENG BIO-PHARMACEUTICAL CO., LTD., BEIJING HUIZHIHENG BIOTECHNOLOGY CO., LTD.
    Inventors: Chutian Shu, Zhenhua Wang
  • Patent number: 10669354
    Abstract: The present invention relates to an improved process for the production of sulfated hyaluronic acid (HA), sulfated HA-derivatives and/or mixtures thereof, having a high purity and a sulfation degree ranging from 1 to 3, which comprises the following steps: a) solubilization of HA-Na or HA-derivative-Na, in an aprotic solvent in the presence of an organic sulfonic acid; b) sulfation of the solution obtained by the addition of an excess of sulfating agents; c) precipitation in ethanol until a precipitate is obtained; d) solubilization of the precipitate thus obtained in a mixture of water and the aprotic solvent used in step a), in the presence of an excess of NaCl, with a pH adjustment within a range of 3 to 4; e) further precipitation with ethanol until a powder is obtained; f) washings of the powder coming from step c) and drying the product thus obtained under vacuum.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: June 2, 2020
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Cristian Guarise, Mauro Pavan
  • Patent number: 10550094
    Abstract: The invention relates to compounds having general formula (I): where R?H, CH2—OH, CH2—O—CO—CH3, CH2—O—CO-Ph (Ph=phenyl) R??H, CH2—O—CO—CH3, CH2—O—CO-Ph (Ph=phenyl) Ar=phenyl, 3-methoxy-4-hydroxy phenyl, 2-furyl. These are compounds having antioxidant activity against free radicals together with anti-inflammatory activity, the compounds being useful as active ingredients for the preparation of pharmaceutical dermatological or cosmetic compositions for skin care.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: February 4, 2020
    Assignee: Giuliana S.P.A.
    Inventors: Giammaria Giuliani, Anna Benedusi, Barbara Marzani, Sergio Baroni
  • Patent number: 10406172
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: September 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Broedl, Rolf Grempler
  • Patent number: 10323050
    Abstract: A non-aqueous electrolyte solution for a battery, including a compound represented by formula (1), wherein each A represents P or P?O; each R represents H, a halogen, an alkyl, an aryl, an alkoxy or an aryloxy; each X represents H, an alkyl, an aryl, an alkali metal or formula (2); each Y represents H, a halogen, an alkyl, an aryl, an alkoxy, an aryloxy or formula (3); each Z represents H, an alkyl, an aryl or OZ1; Z1 represents H, an alkyl, an aryl, an alkali metal, formula (2), or formula (4); each M represents an alkali metal; n is 1 or more; m is 1 or more; l is 1 or more; a sum of n, m and l in one molecule is from 1 to 200; and each * represents a position of bonding:
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: June 18, 2019
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Masataka Miyasato, Satoko Fujiyama, Takashi Hayashi, Takeshi Kobayashi
  • Patent number: 10239910
    Abstract: The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of sofosbuvir, which uses reagents that are less expensive and easier to handle.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: March 26, 2019
    Assignee: OPTIMUS DRUGS (P) LIMITED
    Inventors: Srinivas Reddy Desi Reddy, Srinivas Rao Velivela
  • Patent number: 10117951
    Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: November 6, 2018
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventor: Vincent D. Antle
  • Patent number: 9919995
    Abstract: A photoactivatable caged compound (TPE-C) with AIE characteristics is designed and synthesized. TPE-C is non-emissive either in solution or in aggregated state, but its luminescence can be induced to emit strong cyan emission in aggregated state by UV irradiation. Such property enables TPE-C to be applied in photo-patterning and anti-counterfeiting related areas.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: March 20, 2018
    Inventor: Benzhong Tang
  • Patent number: 9834533
    Abstract: The present invention provides processes for preparing SGLT2 inhibitors, such as dapagliflozin and empagliflozin.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 5, 2017
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Tsung-Yu Hsiao, Jyh-Hsiung Liao
  • Patent number: 9550747
    Abstract: The present invention relates to a new crystalline form of dapagliflozin represented by formula (I). The crystalline form has a characteristic absorption peak at about 4.318 (20.45) in an X-ray powder diffraction pattern shown by angle 2 theta and interplanar spacing (value d). It can be prepared by dissolving dapagliflozin in good organic solvents, adding poor solvents, stirring to crystallization, filtering and drying. The new crystalline form of dapagliflozin of the present invention has the following superior features: good solubility, low hygroscopicity, high stability and good preparation reproducibility.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: January 24, 2017
    Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Xifeng Zhu, Xiaobi Li, Tiancheng Zhang, Fuping Yuan
  • Patent number: 9382336
    Abstract: Provided is a method for preparing a cellulose ether having a low degree of polymerization and undergoing less yellowing and a cellulose ether prepared thereby. Specifically, provided is a method for preparing a cellulose ether having a low degree of polymerization, the method including a step of bringing pulp and an alkali metal hydroxide solution into contact with each other or mixing them to obtain a corresponding alkali cellulose, a first depolymerization step of reacting the alkali cellulose with oxygen to adjust a viscosity reduction percentage of the alkali cellulose to from 10 to 95%, a step of reacting the depolymerized alkali cellulose with an etherifying agent, a step of washing and drying the reaction product to obtain a cellulose ether, and a second depolymerization step of bringing the cellulose ether into contact with hydrochloric acid to adjust a viscosity reduction percentage of the cellulose ether from 40 to 99.9%.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: July 5, 2016
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Mitsuo Narita, Yuichi Nishiyama
  • Patent number: 9315532
    Abstract: Described herein are fatty acid carbohydrate hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: April 19, 2016
    Assignee: The Johns Hopkins University
    Inventors: Kevin J. Yarema, Srinivasa-Gopalan Sampathkumar, Mark B. Jones, Christopher T. Campbell, Udayanath Aich
  • Patent number: 9040250
    Abstract: A composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6. A method of administering to an immunosuppressed patient or a patient diagnosed with sepsis or septic shock a composition having a proanthocyanidin. A method of administering to a patient diagnosed with a gram negative bacterial infection a composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: May 26, 2015
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: James B Delehanty, Brandy J White, Baochuan Lin, Frances S Ligler
  • Publication number: 20150141524
    Abstract: The invention relates to a method for the production of a solid bio-product wherein at least 80% of the original indigestible oligosaccharide (raffmose, stachyose and verbascose) content has been degraded into digestible mono- and disaccharides, comprising the following steps: 1) providing a mixture of milled or flaked or otherwise disintegrated biomass, comprising oligosaccharides and optionally polysaccharides and further comprising proteinaceous plant parts, water and one or more enzyme preparations containing ?-galactosidase(s); 2) reacting the mixture resulting from step (1) under continuous mixing and under conditions where the water content in the initial mixture does not exceed 65% by weight, for 0.15-36 hours at a temperature of about 20-65° C.; 3) incubating the reacted mixture from step (2) at a temperature and in a time period which inactivate said ?-galactosidase(s), as well as solid bio-products obtainable by such method.
    Type: Application
    Filed: May 5, 2013
    Publication date: May 21, 2015
    Applicant: Hamlet Protein A/S
    Inventors: Katrine Hvid Ellegard, Karl Kristian Thomsen, Ole Kaae Hansen
  • Patent number: 9017943
    Abstract: Small molecule fluorescent probes for established drug targets such as nucleic acids including DNA and RNA has been developed and disclosed herein. These nucleic acid probes bind to multiple DNA and RNA structures, and to sites crucial for nucleic acid function, such as DNA and RNA major grooves. Displacement of the probes by other binders such as small molecule compounds and/or proteins illicits a fluorescence change in the probe that once detected and analyzed provide binding information of these other binders of interest. Similarly, changes in fluorescence upon binding of the probes to nucleic acid have been applied to screen nucleic acid of different sequence and conformation. The nucleic acid probes and method of uses disclosed herein are advantageously suitable for high-through put screening of libraries of small molecule compounds, proteins, and nucleic acids.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: April 28, 2015
    Assignee: Nubad LLC
    Inventors: Dev P. Arya, Frank Anderson Norris, Jason Derrick Watkins
  • Patent number: 9011928
    Abstract: Compositions and methods of using the compositions are provided for forming an embolus within a region of an anatomical lumen for a transitory period in order to achieve a therapeutic effect.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: April 21, 2015
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Wouter E. Roorda, Stephen D. Pacetti
  • Patent number: 9012412
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 21, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Bao-Ping Zhao
  • Patent number: 9006403
    Abstract: Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 14, 2015
    Assignee: Theracos, Inc.
    Inventors: Jason Liou, Yuelin Wu, Shengbin Li, Ge Xu
  • Patent number: 8986933
    Abstract: A process for detecting human rhinovirus nucleic acid in a biological sample, includes producing an amplification product by amplifying an human bocavirus nucleotide sequence using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and measuring said amplification product to detect human rhinovirus in said biological sample. Also provided are reagents and methods for detecting and distinguishing human rhinovirus from other viruses. A kit is provided for detecting and quantifying human rhinovirus in a biological sample.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: March 24, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control
    Inventors: Xiaoyan Lu, Dean Erdman
  • Patent number: 8986667
    Abstract: The present invention relates to a mixture, having a skin-tightening effect, which is made up of: 10 to 80% by weight of a polysaccharide, preferably of an alginate, having a molecular weight of less than 600,000 Daltons, preferably less than 400,000 Daltons and more preferably less than 200,000 Daltons, 15 to 75% by weight of a polyhydroxylated agent selected from sugars and their derivatives, particularly sugar esters and sugar, ethers, preferably sorbitol, 3 to 15% by weight of poly(vinyl alcohol) or polyvinylpyrrolidone, and 0 to 25% by weight of cellulose or of a derivative of cellulose, such as carboxymethylcellulose or hydroxymethylcellulose. The present invention also relates to cosmetic compositions which contain this mixture. These cosmetic compositions enable a mechanical smoothing of the surface of the skin to be obtained progressively with great comfort of use and enables a good fixing of make-up products.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: March 24, 2015
    Assignee: LVMH Recherche
    Inventors: Hervé Delage-Grouiller, Brigitte Noe, Christian Mahe
  • Patent number: 8974793
    Abstract: Described herein are methods and systems that can be used to induce immunologic tolerance to non-self antigens. The methods and systems comprise introducing a tolerogen comprising at least one immunogenic non-self antigen coupled to a carrier, wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. The non-self antigen can be selected from the group consisting of carbohydrate antigens, full-length antigenic proteins, and fragments and combinations thereof, while the carrier can be selected from nanoparticles and stents. Tolerogen compositions are also provided and can be used to induce immunologic tolerance to non-self antigens. These methods, systems and compositions are particularly advantageous since they can be used to allow for the extension of the window of safety for immunologically-incompatible transplantations to patients who are growing past the age of infancy.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: March 10, 2015
    Assignee: The Governors Of The University Of Alberta
    Inventors: Lori Jeanne West, Todd Lambert Lowary, Jillian Mary Buriak, Brian Daly, Mylvaganam Jeyakanthan, Peter John Meloncelli, Vincent Arthur Wright, Anne Margaret Cooper
  • Patent number: 8957033
    Abstract: Disclosed is a compound of formula I, or a pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof, wherein R1 and R2 are each independently hydrogen, —OH, alkyl, —CF3, —OCHF2, —OCF3 or halogen; R3 is cycloalkyl, —OCH2CF3, —OCH2CHF2, —OCH2CH2F or —OCH2CH3; R4 is hydrogen, —OH, —O aryl, —OCH2 aryl, alkyl, cycloalkyl, —CF3, —OCHF2, —OCF3, —OCH2CF3, —OCH2CHF2, —OCH2CH2F or halogen; A is —CX1X2, wherein X1 and X2 are each independently H, F and Cl, and when both X1 and X2 are H, R3 is not —OCH2CH3. The compound has an activity of inhibitors of sodium-dependent glucose transport protein. Also disclosed is a method for preparing the compound, a pharmaceutical composition comprising the compound, use of the compound and pharmaceutical composition thereof in preparing medicaments of SGLT2 inhibitors and treating related diseases.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: February 17, 2015
    Assignee: Beijing Prelude Pharm. SCI. & Tech. Co., Ltd.
    Inventor: Michael Wang
  • Patent number: 8952139
    Abstract: The present invention provides processes (e.g., arylation reaction) for stereoselectively preparing C-arylglucosides that can be useful as synthetic building block or drugs, including SGLT2 inhibitors.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: February 10, 2015
    Assignee: ScinoPharm Taiwan, Ltd
    Inventors: Julian Paul Henschke, Chen-Wei Lin, Ping-Yu Wu, Chi-Nung Hsiao, Jyh-Hsiung Liao, Tsung-Yu Hsiao
  • Publication number: 20150017246
    Abstract: The invention provides novel chemical entities based on sugar alcohols. These new chemical entities are biocompatible and biodegradable. The molecules can be made in a single and pure form. The molecular weights of these molecules range from small (<1000 Da) to large (1000-120,000 Da). The sugar alcohol-based molecules can have functional groups throughout the molecule for crosslinking compounds, such as the preparation of antibody-drug conjugates, or to facilitate the delivery of therapeutic proteins, peptides, siRNA, and chemotherapeutic drugs. Also provided are new conjugate entities prepared through sugar alcohol molecules. Methods of synthesizing sugar alcohol-based molecules and conjugates are also within the scope of the invention.
    Type: Application
    Filed: January 15, 2014
    Publication date: January 15, 2015
    Applicant: CellMosaic, Inc.
    Inventor: Yumei Huang
  • Publication number: 20150017098
    Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.
    Type: Application
    Filed: October 20, 2011
    Publication date: January 15, 2015
    Inventors: Junji Kato, Rishu Takimoto
  • Patent number: 8927497
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 6, 2015
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Patent number: 8927506
    Abstract: Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: January 6, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Publication number: 20150005484
    Abstract: A method for saccharification of lignocellulosic biomass, the method comprising (1) a pretreatment step of impregnating lignocellulosic biomass with an aqueous alkali solution, subjecting the resultant mixture to solid-liquid separation to remove part of the aqueous alkali solution, and then performing heat treatment, and (2) a saccharification step of enzymatically degrading the lignocellulosic biomass resulting from the pretreatment step to obtain a saccharified liquid can be applied to high-lignin lignocellulosic biomass, reduce the usage of alkali and water in the pretreatment step, increase the sugar yield in the saccharification step, decrease the reaction time, reduce enzyme adsorption on a biomass residue, and improve the enzyme recovery rate.
    Type: Application
    Filed: January 23, 2013
    Publication date: January 1, 2015
    Inventor: Takafumi Kubo
  • Publication number: 20140357580
    Abstract: Antimicrobial compounds from Epicoccum purpurascens (syn. E. negrum) for use against plant and fungi pathogens. An orange yellow metabolite was isolated, the structure elucidated as a small group of compounds Epipyrone A-C and fungicidal activity demonstrated against plant pathogens, for example Botrytis cinerea and Lecanicillium muscarium. Agricultrual and pharmaceutical compositions are provide, and use thereof in treating microbial infections in an animal or plant are also provided.
    Type: Application
    Filed: August 21, 2014
    Publication date: December 4, 2014
    Inventors: Roel van Ginkel, Andrew Ian Selwood, Alistair Lawrence Wilkins, Stephen Ford
  • Publication number: 20140348746
    Abstract: The invention relates to a family of compounds that comprise fluorescent cyanine dyes. The compounds are near infrared absorbing heptamethine cyanine dyes with a 4,4-disubstituted cyclohexyl ring as part of the polymethine chromophore. The compounds are generally hydrophilic and can be chemically linked to biomolecules, such as proteins, nucleic acids, and therapeutic small molecules. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications.
    Type: Application
    Filed: March 17, 2014
    Publication date: November 27, 2014
    Applicant: VisEn Medical, Inc.
    Inventor: Narasimhachari Narayanan
  • Patent number: 8889637
    Abstract: The present invention relates to novel polymorphs of the trisaccharide 2?-O-fucosyllactose (2-FL) of formula (1), methods for producing said polymorphs and their use in pharmaceutical or nutritional compositions.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: November 18, 2014
    Assignee: Glycom A/S
    Inventors: Károly Ágoston, István Bajza, Gyula Dekany, Péter Trinka, Ágnes Ágoston, Gábor Kádár, Sándor Demkó, Ignacio Figueroa-Pérez, Markus Hederos, Ferenc Horváth, Andreas Schroven, Ioannis Vrasidas, Piroska Kovács-Pénzes, Christian Risinger, László Kalmár, Gergely Pipa, Julien Boutet, Lars Kröger, Christoph Röhrig
  • Publication number: 20140329286
    Abstract: The present invention relates to a processed food composition containing, as an active ingredient, psicose, which is a saccharide having the function of stimulating a daidzein conversion into equol by an intestinal microorganism in the human body.
    Type: Application
    Filed: October 15, 2012
    Publication date: November 6, 2014
    Inventors: Taek Beom Kim, Seong Bo Kim, Min Hae Kim, Sung Jae Yang, Jae Hong Han
  • Publication number: 20140322198
    Abstract: The invention relates to an active ingredient and/or to a composition having beneficial effect on neurological and cognitive functions.
    Type: Application
    Filed: November 29, 2012
    Publication date: October 30, 2014
    Inventors: Sybille Buchwald-Werner, Hajime Fujii
  • Patent number: 8871743
    Abstract: A composite of bacterial cellulose and capsules embedded therein is prepared, for example calcium alginate capsules encapsulating functional components being discretely embedded in a matrix of Gluconacetobacter xylinus cellulose. The functional components may be drugs, probiotics or nutrients, such as fungal polysaccharide.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: October 28, 2014
    Assignee: Food Industry Research and Development Institute
    Inventors: Pei-Ying Chen, Jinn-Tsyy Lai, Hsu-Chou Hsiao, Yan-Hwa Chu, Chii-Cherng Liao
  • Publication number: 20140316119
    Abstract: A composition for improving biometabolism parameters is provided. The composition contains D-psicose as an active ingredient, and is continuously ingested in a dose of 5 g or more per intake in terms of D-psicose to lower biometabolism parameters represented by a uric acid level and/or a liver function indicator component level. ?-GTP showed a significant decrease after 4 weeks from 15-g ingestion. ?-GTP and ALP showed a significant decrease after 4 weeks and 2 weeks, respectively, from the ingestion of D-psicose continuously administered three times each day in a dose of 5 g or more per intake.
    Type: Application
    Filed: August 8, 2012
    Publication date: October 23, 2014
    Applicants: MATSUTANI CHEMICAL INDUSTRY CO., LTD., RARE SUGER FOODS, LLC.
    Inventors: Koji Yamada, Noriko Hayashi, Takako Yamada
  • Publication number: 20140315833
    Abstract: A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.
    Type: Application
    Filed: April 21, 2014
    Publication date: October 23, 2014
    Inventors: Anders Berkenstam, Edward Kuczynski, Alf S. Andersson, Jan-Ake Gustafsson, Carly Sue Filgueira
  • Patent number: 8853169
    Abstract: The present invention relates to novel C-glycoside compounds of given absolute configuration, to a process for synthesizing them and to compositions containing them. The invention also relates to the cosmetic use of these C-glycoside compounds as agents to stimulate the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and/or of proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and/or keratinocytes. The invention also relates to a cosmetic process for treating keratin materials using a composition containing at least one C-glycoside compound according to the invention.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: October 7, 2014
    Assignee: L'Oreal
    Inventors: Simon Trouille, Alexandre Cavezza, Patrick Pichaud
  • Patent number: 8853372
    Abstract: A novel saccharide siloxane copolymer has improved stability in the presence of water as compared to certain previously known saccharide siloxanes. The saccharide siloxane copolymer is useful in personal care compositions.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: October 7, 2014
    Assignee: Dow Corning Corporation
    Inventors: James Anderson Beck, Lylenette Canfield, Michael Salvatore Ferritto, Eric Jude Joffre, Mark Keinath, Feifei Lin, Anil Kumar Tomar
  • Patent number: 8853385
    Abstract: The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: October 7, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kiichiro Ueta, Kenji Arakawa, Yasuaki Matsushita
  • Patent number: 8846880
    Abstract: The present invention relates to novel synthetic analogs of phosphatidyl-myo-inositol mannosides (hereinafter referred to as PIMs) of general formula (I): or a pharmaceutically acceptable salt thereof, to the method for preparing same and to the use thereof in the prevention or treatment of a disease associated with the overexpression of cytokines or of chemokines, in particular of TNF and/or of IL-12. The invention also relates to a pharmaceutical composition comprising at least one synthetic derivative of PIM.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: September 30, 2014
    Assignees: Centre National de la Recherche Scientifique—CNRS—, Universite d'Orleans
    Inventors: Valérie Quesniaux Ryffel, Olivier Martin, Sophie Front
  • Publication number: 20140288298
    Abstract: The present invention provides a method for efficiently producing monosaccharides, oligosaccharides, and furfurals from biomass. A biomass is hydrolyzed under conditions under which monosaccharides, oligosaccharides, and furfurals are produced while continuously supplying an aqueous suspension of the biomass from a supply port of a continuous primary hydrolysis device and moving the suspension through the device. A hydrolysis solution is continuously discharged from a discharge port of the continuous hydrolysis device, and a hydrolysis solution containing monosaccharides, oligosaccharides, and furfurals are extracted from an intermediate extraction port provided at any position between the supply port and the discharge port of the continuous primary hydrolysis device. The extracted hydrolysis solution is then subjected to secondary hydrolysis.
    Type: Application
    Filed: November 2, 2012
    Publication date: September 25, 2014
    Applicant: Oji Holdings Corporation
    Inventors: Seiji Nakagame, Nobuhisa Dano, Takayuki Obuchi, Shinya Hagiwara, Yosuke Uchida, Koki Kisara, Tomoaki Sasaki
  • Publication number: 20140273108
    Abstract: A method of producing hydrolysate from cellulosic material by adding hydrothermally treated stillage or a fraction thereof to cellulosic material, treating the mixture of hydrothermally treated stillage and cellulosic material with at least one hydrolyzing enzyme, and hydrolyzing and converting complex carbohydrates in the cellulosic material. The hydrolysate produced by the method. Ethanol, organic acids, and organism metabolites produced by the method. Biomass produced by the method. A method of increasing sugar production rate and yield of sugars from cellulosic material by adding hydrothermally treated stillage or a fraction thereof to cellulosic material, treating the mixture of hydrothermally treated stillage and cellulosic material with at least one hydrolyzing enzyme, and hydrolyzing complex carbohydrates in the cellulosic material and forming sugars.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: Valicor, Inc
    Inventor: James Robert Bleyer
  • Publication number: 20140271632
    Abstract: The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: AbbVie, Inc.
    Inventors: Patrick Hossler, Sean McDermott, Christopher Racicot, Ivan Correia
  • Patent number: 8835396
    Abstract: This invention discloses a method and compositions for treatment or prevention of pulmonary hypertension in a mammal. Representative mammals include humans and horses. The invention further relates to supplements especially beneficial in preventing or stopping the progression of pulmonary hypertension. The supplements include ribose and folate. Additional nutrients include omega-3 fatty acids and gamma-linolenic acid.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: September 16, 2014
    Assignee: Bioenergy, Inc.
    Inventors: George Verlaan, John A. St. Cyr
  • Publication number: 20140256921
    Abstract: Disclosed is a method for producing a tetrahydropyran compound represented by general formula (5) shown in the scheme. Accordingly, a tetrahydropyran derivative is obtained in high yield and with high selectivity without using a highly toxic reagent, and an industrially useful method for producing a tetrahydropyran derivative and an intermediate thereof can be provided. In formulae (1) to (5), R1 and R2 each independently represent a hydrogen atom, a linear, branched, or cyclic alkyl group, or an aromatic group which may have a substituent, and R1 and R2 may be combined to form an alkylene group, thereby forming a ring; and R3 and R4 each independently represent a hydrogen atom or a linear, branched, or cyclic alkyl group, and R3 and R4 may be combined to form an alkylene group, thereby forming a ring.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Hirotaka KAWANAMI, Kana YAMAGUCHI, Shota MURASE
  • Publication number: 20140256657
    Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein A, R1, R2, R3, R4, and R5 are as defined herein, useful as dual SGLT1/SGLT2 inhibitors.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Micheal Gaul, Gee-Hong Kuo, Guozhang Xu, Bao-Ping Zhao
  • Patent number: 8829167
    Abstract: Foliamngiferosides having the general formula (I) are disclosed, wherein R is H or —OCH. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of ?-glucosidase are also disclosed. The foliamangiferosides can be used in preparing drugs for treating diabetes.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: September 9, 2014
    Assignee: Tianjin University of Traditional Chinese Medicine
    Inventors: Tao Wang, Yi Zhang, Erwei Liu, Lifeng Han, Dandan Ge, Xiumei Gao
  • Publication number: 20140243283
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
    Type: Application
    Filed: December 18, 2013
    Publication date: August 28, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Yeeman K. Ramtohul, Sanjoy Kumar Das, Caroline Cadilhac, Thumkunta Jagadeeswar Reddy, Louis Vaillancourt, Michel Gallant, Bingcan Liu, Evelyne Dietrich, Frederic Vallee, Julien Martel, Carl Poisson